Details of the Drug Pharmacogenomic Perturbation Atlas

Loteprednol Etabonate Drug Info

Alrex; Locort; Loteflam; Lotemax; Loterox; CDDD-5604; HGP-1; IDR-90102; IDR-90103; Lotemax (TN); P-5604; Alrex, Lotemax, Loteprednol etabonate; Loteprednol etabonate (JAN/USAN); Chloromethyl 17alpha-[(ethoxycarbonyl)oxy]-11beta-hydroxy-3-oxoandrosta-1,4-diene-17beta-carboxylate; Chloromethyl (8S,9S,10R,11S,13S,14S,17R)-17-ethoxycarbonyloxy-11-hydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-17-carboxylate

Therapeutic Class

Antiallergic Agents

Cross-matching ID

PubChem CID

444025

ChEBI ID

CHEMBL1200865

CAS Number

CAS 82034-46-6

TTD Drug ID

D0X6GN

INTEDE Drug ID

DR0985

General Information of Drug (ID: DM8QTJI)

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Proximal tubule bicarbonate reclamation	2.11	0.00e+0	21/23 (91.3%)	SLC4A4;PCK1;FXYD2;...
Pentose and glucuronate interconversions	1.98	1.19e-2	17/34 (50%)	AKR1B1;DCXR;AKR1B10;...
Complement and coagulation cascades	1.98	7.91e-3	76/85 (89.41%)	PLAT;SERPINE1;CFD;...
Fatty acid degradation	1.97	5.93e-3	40/43 (93.02%)	ECI2;EHHADH;ADH5;...
Drug metabolism	1.95	6.33e-3	78/151 (51.66%)	MAOA;HPRT1;ADH5;...
PPAR signaling pathway	1.85	1.05e-2	66/74 (89.19%)	PCK1;HMGCS1;FABP5;...
Histidine metabolism	1.83	1.47e-2	16/22 (72.73%)	MAOA;AOC1;HAL;...
Thermogenesis	1.83	1.29e-2	173/232 (74.57%)	MGLL;NDUFB7;MAP3K5;...
Valine, leucine and isoleucine degradation	1.82	1.14e-2	42/48 (87.5%)	DLD;HMGCS1;EHHADH;...
Renin-angiotensin system	1.78	1.98e-2	20/23 (86.96%)	ANPEP;ENPEP;AGTR1;...
Propanoate metabolism	1.77	1.94e-2	30/34 (88.24%)	DLD;EHHADH;ACOX1;...
Mineral absorption	1.75	2.44e-2	48/60 (80%)	MT1M;FXYD2;MT1E;...
Tryptophan metabolism	1.74	2.31e-2	35/42 (83.33%)	DLD;MAOA;AOC1;...
Terpenoid backbone biosynthesis	1.72	2.60e-2	18/22 (81.82%)	HMGCS1;ACAT1;ACAT2;...
Oxidative phosphorylation	1.70	2.64e-2	93/133 (69.92%)	NDUFB7;ATP5PD;COX17;...
Nitrogen metabolism	1.65	4.75e-2	16/17 (94.12%)	CA12;CPS1;CA2;...
Tyrosine metabolism	1.64	4.93e-2	30/36 (83.33%)	MAOA;ADH5;ADH1C;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	10uM	6H, 24H

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	10uM	6H

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	10uM	6H

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	10uM	6H, 24H

Prostate

Prostate carcinoma

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	10uM	6H